Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, Gonzalez RM, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova OV, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue BJ, Grajales-Cruz AF, Castaneda Puglianini OA, Liu HD, Nishihori T, Freeman CL, Brayer JB, Shain KH, Baz RC, Locke FL, Alsina M, Sidana S, Hansen DK. Logue JM, et al. Among authors: freeman cl. Blood Adv. 2022 Dec 27;6(24):6109-6119. doi: 10.1182/bloodadvances.2022008320. Blood Adv. 2022. PMID: 35939783 Free PMC article.
The outcome of older adults with classic Hodgkin lymphoma in British Columbia.
Cheng PTM, Villa D, Gerrie AS, Freeman CL, Slack GW, Gascoyne RD, Farinha P, Craig JW, Skinnider B, Wilson D, Scott DW, Connors JM, Sehn LH, Savage KJ. Cheng PTM, et al. Among authors: freeman cl. Blood Adv. 2022 Nov 22;6(22):5924-5932. doi: 10.1182/bloodadvances.2022008258. Blood Adv. 2022. PMID: 36075016 Free PMC article.
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier C, Blue BJ, Brayer J, Chandrasekhar S, Grajales Cruz A, De Avila G, Elmariah H, Faramand R, Freeman C, Jain M, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Lee DH, et al. Blood Adv. 2023 Aug 22;7(16):4247-4257. doi: 10.1182/bloodadvances.2023009766. Blood Adv. 2023. PMID: 37307173 Free PMC article.
CARs put age in the rearview mirror.
Freeman CL, Locke FL. Freeman CL, et al. Blood. 2023 Sep 21;142(12):1029-1031. doi: 10.1182/blood.2023021094. Blood. 2023. PMID: 37733380 Free article. No abstract available.
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Freeman CL, et al. Clin Cancer Res. 2023 Nov 14;29(22):4575-4585. doi: 10.1158/1078-0432.CCR-22-3987. Clin Cancer Res. 2023. PMID: 37735756
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Peres LC, et al. Among authors: freeman cl. Blood Adv. 2024 Jan 9;8(1):251-259. doi: 10.1182/bloodadvances.2023010894. Blood Adv. 2024. PMID: 37855718 Free PMC article.
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: freeman cl. Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945. Blood. 2025. PMID: 39365257
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes.
Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Freeman CL, et al. Blood. 2024 Dec 9:blood.2024024965. doi: 10.1182/blood.2024024965. Online ahead of print. Blood. 2024. PMID: 39652773
Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel: A CIBMTR Study.
Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD Jr, Pasquini MC, Usmani SZ, Freeman CL. Akhtar OS, et al. Among authors: freeman cl. Blood Adv. 2024 Dec 30:bloodadvances.2024014970. doi: 10.1182/bloodadvances.2024014970. Online ahead of print. Blood Adv. 2024. PMID: 39786391
104 results